Op-ed: DEA and FDA rules exacerbate Adderall shortage

Josh Disbrow is chairman and chief executive officer of Aytu BioPharma, which makes a competing drug to treat ADHD called Adzenys XR-ODT. A nationwide shortage of Adderall has left many patients struggling to manage their attention deficit hyperactivity disorder, better known as ADHD. From all…#joshdisbrow #aytubiopharma #adzenysxrodt #adderall #scheduleii #dea #adderallxr #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news